CluePoints

Clinical trial complexity is now the norm: more endpoints, more procedures, narrower eligibility criteria, and more data sources, with Phase III protocols collecting approximately 5.9 million data points on average and volume rising around 11% annually si

Intelligent Query Detection, Medical & Safety Review and Intelligent Medical Coding are now generally available, extending CluePoints' science-first approach from RBQM into clinical data review. The partner will join CluePoints live at SCDM 2026 to celebr

New peer-reviewed research puts hard numbers to the financial value of RBQM, showing ROI multiples up to 23x and up to 19% shorter clinical phase durations, with time savings as the biggest driver. The post Making the Financial Case for Risk-Based Quality

Clinical research associates are evolving from compliance-focused manual monitors to data-enabled strategic site partners, but organizations need analytics training, clear operating models, and active change management to make the shift stick. The post Th

Clinical trials have undergone a period of immense change. Use of real-world data (RWD) is increasing. Regulators are backing both risk-based approaches and the use of real-world evidence (RWE). Artificial intelligence (AI) allows us to unlock better insi